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Abstract
Background: The objective of this study was to examine Streptococcus pneumoniae isolates collected from a
longitudinal surveillance program in order to determine their susceptibility to currently used fluoroquinolones and
of the frequency and type of mutations in the quinolone-resistant determining regions (QRDRs) of their parC and
gyrA genes.
Methods: The Canadian Bacterial Surveillance Network has been collecting clinical isolates of S. pneumoniae from
across Canada since 1988. Broth microdilution susceptibility testing was carried out according to the Clinical and
Laboratory Standards Institute guidelines. The QRDRs of the parC and gyrA genes were sequenced for all isolates
with ciprofloxacin MIC ≥ 4 mg/L, and a large representative sample of isolates (N = 4,243) with MIC ≤ 2 mg/L.
Results: A total of 4,798 out of 30,111 isolates collected from 1988, and 1993 to 2007 were studied. Of those
isolates that were successfully sequenced, 184 out of 1,032 with mutations in parC only, 11 out of 30 with
mutations in gyrA only, and 292 out of 298 with mutations in parC and gyrA were considered resistant to
ciprofloxacin (MIC ≥ 4 mg/L). The most common substitutions in the parC were at positions 137 (n = 722), 79 (n =
209), and 83 (n = 56), of which substitutions at positions 79 and 83 were associated with 4-fold increase in MIC to
ciprofloxacin, whereas substitutions at position 137 had minimal effect on the ciprofloxacin MIC. A total of 400 out
of 622 isolates with Lys-137 parC mutation belonged to serotypes 1, 12, 31, 7A, 9V, 9N and 9L, whereas only 49 out
of 3064 isolates with no mutations belonged to these serotypes. Twenty-one out of 30 isolates with substitutions
at position 81 of the gyrA gene had an increased MIC to ciprofloxacin. Finally, we found that isolates with
mutations in both parC and gyrA were significantly associated with increased MIC to fluoroquinolones.
Conclusions: Not all mutations, most frequently Lys-137, found in the QRDRs of the parC gene of S. pneumoniae is
associated with an increased MIC to fluoroquinolones. The high prevalence of Lys-137 appears to be due to its
frequent occurrence in common serotypes.
Background
Streptococcus pneumoniae is a common cause of acute
exacerbation of chronic bronchitis, sinusitis, and com-
munity-acquired pneumonia [1-3]. Treatment of respira-
tory tract infections has relied primarily on the use of b-
lactam and macrolide antimicrobials; however in recent
years the emergence of resistance to these agents has
led to the widespread use of fluoroquinolones for adult
patients with respiratory disease [4-7].
From the mid 1980s until the later part of the 1990s,
earlier generation fluoroquinolones such as ciprofloxacin
and ofloxacin were widely used for treatment of respira-
tory tract infections, despite having less than optimal
activity against pneumococci. However, since the late
1990s, levofloxacin and moxifloxacin, with much greater
in vitro activity and more optimal pharmacokinetic and
pharmacodynamic properties for the treatment of pneu-
mococcal infections, have replaced these agents [8,9].
Fluoroquinolones target one of the two type II topoi-
somerases of pneumococci, DNA gyrase (composed of
GyrA and GyrB subunit) and/or topoisomerase IV
(composed of ParC and ParE subunits), resulting in
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ibility of S. pneumoniae to the fluoroquinolones has
been attributed to either chromosomal mutations in the
quinolone resistance-determining regions (QRDRs) of
the parC and/or gyrA genes, which encode for subunits
of topoisomerase IV and DNA gyrase, respectively, and/
or by a reserpine-sensitive efflux mechanism [13-16].
Fluoroquinolones have binding preferences (primacy)
for one of the enzymes found in the two type II topoi-
somerases. Primacy is determined most reliably by in
vitro selection experiments in which a resistance muta-
tion is observed first in one of the two genes of the pri-
mary target and gene mutations in the secondary target
are only observed subsequently [17]. Mutant selection
studies in S. pneumoniae have shown that the primary
target for fluoroquinolones, such as ciprofloxacin, oflox-
acin and levofloxacin, is topoisomerase IV. In contrast,
newer fluoroquinolones such as moxifloxacin, gatifloxa-
cin and gemifloxacin primarily target DNA gyrase
[18,19]. In fact, gemifloxacin and moxifloxacin have
been found in some reports to exhibit dual activity
based on the minimal effect of either gyrA or parC
mutations on resistance, whereas strains with mutations
in both gyrA and parC exhibit high-level resistance to
these agents [20-22].
Previous studies have shown that pneumococci with
substitutions at positions 79 and 83 of parC, and 81 and
85 of gyrA are most frequently found in isolates with
reduced susceptibility to fluoroquinolones [23-32]. How-
ever, many of these studies only sequenced isolates that
were resistant to fluoroquinolones, were smaller in sam-
ple size, and had been done in a time before the wide-
spread use of the newer generation fluoroquinolones.
The purpose of this study was to characterize a large
collection of contemporary isolates of pneumococci in
order to identify mutations in the QRDR of their parC
and gyrA genes, and to determine the effect of these
mutations on fluoroquinolone activity.
Materials and methods
The Canadian Bacterial Surveillance Network is com-
prised of more than 100 private laboratories and com-
munity and university-affiliated hospitals in all 10
provinces and 2 of 3 territories in Canada. In 1988, and
in each year from 1993 to 2008, participating labora-
tories were asked, based on their size, to collect either
the first 20 (for small laboratories) or the first 100 (for
larger laboratories) consecutive clinical isolates, and
then all sterile site isolates of S. pneumoniae.T h ed a t e
of collection, the source of the specimen, and the
patient’s age and sex were recorded on a standard form.
Duplicate isolates from the same patient were excluded.
Isolates were transported on chocolate agar slants or
swabs to a central laboratory where they were confirmed
to be S. pneumoniae by standard methodology and
stored at -70°C. Prior to susceptibility testing, isolates
were thawed and subcultured onto blood agar twice.
Isolates were serotyped on the basis of capsular polysac-
charide antigens by the quelling reactions [33]. In vitro
broth microdilution susceptibility testing was performed
and interpreted according to Clinical and Laboratory
Standards Institute (CLSI) guidelines [34,35]. Isolates
were classified as non-susceptible to an antimicrobial if
their MICs were in either the intermediate or resistant
category, and resistant to ciprofloxacin if their MIC was
≥4 mg/L.
Amplification and sequencing of QRDRs
The QRDRs of the parC and gyrA genes were amplified
using following primers: for parC (forward:
CGGTTCAACGCCGTATTCTT, reverse: ATCC-
CAGTCGAACCATTGAC; 394 bp), gyrA (forward:
TGTTCACCGTCGCATTCTCT, reverse: ATAC-
CAGTTGCTCCATTAACC, 393 bp). Amplicons were
sequenced at Agencourt Bioscience Corp. (Beverly, MA).
Multiple nucleotide sequences were performed with the
ClustalW2 program http://www.ebi.ac.uk/Tools/clus-
talw2/index.html. Both parC and gyrA genes of isolates
with a ciprofloxacin MIC ≥ 4m g / L ,al e v o f l o x a c i nM I C
≥ 4 mg/L or a moxifloxacin MIC ≥ 0.5 mg/L were
amplified and sequenced (N = 540). In addition, a 45%
sample of isolates (N = 2,102) with a ciprofloxacin MIC
=2m g / L ,o ral e v o f l o x a c i nM I Co f=2m g / La n do ra
moxifloxacin MIC = 0.25 mg/L, and a 12% sample of
other isolates (N = 27,469) were also amplified and
sequenced.
Statistical Analysis
Differences in group proportions were assessed with the
chi square test for trend or fisher’s exact test.
Results and Discussion
A total of 30,111 isolates were collected from 1988, and
1993 to 2007. Of these isolates, 11,403 (37.9%) were
recovered from a sterile site (10,565 from blood, 371
from CSF, and 467 from other sterile sites), and 18,601
(61.8%) were from non-sterile sites (9,694 from sputum,
4,732 from eye, 1,988 from ear, 1,053 from bronchial
washings, and 1,134 from other non-sterile sites). Over-
all, 534 out of 30,111 (1.8%) of isolates were resistant to
ciprofloxacin (MIC ≥ 4 mg/L); 360 (1.2%) were non-sus-
ceptible to levofloxacin (MIC ≥ 4 mg/L), and 283 (1.1%)
were non-susceptible to moxifloxacin (MIC ≥ 2 mg/L).
We selected 4,798 isolates for molecular characteriza-
tion of parC and gyrA genes. Of these, 517 out of 534
isolates with ciprofloxacin MIC ≥ 4m g / L ,9 6 8o u to f
968 isolates with MIC = 2 mg/L, and 3,267 out of 3,296
isolates with MIC < 2 mg/L were successfully
sequenced. As shown in Table 1, 1,032 isolates con-
tained at least one mutation in parC,3 0i s o l a t e s
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contained at least one mutation in both parC and gyrA.
Of those parC only mutant isolates, 17.8% were resistant
to ciprofloxacin, 2.2% were non-susceptible to levofloxa-
cin, and 0.4% to moxifloxacin. Among gyrA only mutant
isolates, 36.7% were resistant to ciprofloxacin, 36.7% and
20% non-susceptible to levofloxacin and moxifloxacin,
respectively. Finally, among isolates containing muta-
tions in both parC and gyrA, 98.0% were resistant to
ciprofloxacin, 97.6% non-susceptible to levofloxacin, and
86.2% to moxifloxacin (Table 1).
Among isolates with parC only mutations, the most
common mutations were at positions 137 (Lys-137) (N
= 722, 70.0%), 79 (Ser-79) (N = 209, 20.2%), and 83
(Asp-83) (N = 56, 5.4%) (Table 2). The most common
substitutions observed were Lys137Asn, Ser79Phe or
Tyr, and Asp83Tyr or Asn. As shown in figure 1A, sub-
stitutions at both positions 79 (Ser-79) and 83 (Asp-83)
were associated with four-fold increase in MIC to cipro-
floxacin (P < 0.0001). In contrast, substitution at posi-
tion 137 (Lys-137) was not associated with increased
MIC to ciprofloxacin when compared to isolates with
no mutations in parC (Figure 1A). These data are con-
sistent with previous studies in which isolates with
mutations that resulted in Ser-79 or Asp-83 amino acid
changes were associated with decreased susceptibility to
the fluoroquinolones [25,26,28,31]. Other mutations
were found much less commonly. Those occurring at
position 78 (Asp-78), and possibly those at positions 52
(Ser-52), 91 (Asn-91), 115 (Ala-115) and 129 (Tyr-129)
could be associated with increase MIC to ciprofloxacin,
though statistical analyses were not done due to small
number of isolates (Table 2). The presence of Ser-79
and Asp-83 mutations were associated with an
approximately two fold increase in levofloxacin and
moxifloxacin MICs, though none of the isolates with an
amino acid change a position 83, and only 1.6% and
4.3% of isolates with Ser-79 mutations were non-suscep-
tible to moxifloxacin and levofloxacin, respectively (data
n o ts h o w n ) .H o w e v e r ,i ti si m p o r t a n tt on o t et h a tt h e
classification of non-susceptibility is based on CLSI
breakpoints. S. pneumoniae can just as readily develop
resistance to fluoroquinolones during therapy when a
first-step mutation has occurred that results in reduced
susceptibility to the fluoroquinolones, even though the
increase in MIC does not meet CLSI criteria for non-
susceptibility. The combination of two mutations, each
of which causes a reduction in the activity of the fluoro-
quinolone, results in a resistant strain [36,37].
We found that not all mutations resulted in a reduc-
tion of the activity of the fluoroquinolones. An amino
acid change at Lys-137 in combination with a change in
either Ser-79 or Asp-83did not significantly increased
the ciprofloxacin MIC compared to isolates with Ser-79
or Asp-83 only changes (Ser-79 only vs Ser-79 + Lys-
137: P = 0.330; Asp-83 only vs Asp-83 + Lys-137: P =
0.5511). These data are consistent with previously
reported studies in which a mutation at parC resulting
in an amino acid change at Lys-137 did not play a sig-
nificant role in increasing the MIC to fluoroquinolones
[30,32].
If the Lys-137 parC mutation has only a marginal
effect, if any, on fluoroquinolone activity, what would
explain its presence and the frequency with which has
been identified by others [38]? Its occurrence may just
be the result of a polymorphism in parC,s i m i l a rt o
what has been seen in Streptococcus pyogenes [39] or as
yet some unidentified fitness advantage. The frequency
Table 1 In vitro activities of fluoroquinolones against S. pneumoniae isolates with mutations in the parC and gyrA
genes.
Minimum Inhibitory Concentration (mg/L)
Number of Isolates
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 Total
parC only
Ciprofloxacin 0 0 0 0 2 182 408 256 136 39 5 2 2 0 1032
Levofloxacin 0 0 1 0 0 205 580 213 15 3 4 1 0 0 1022
Moxifloxacin 0 5 130 489 343 16 8 2 1 1 0 0 0 0 995
gyrA only
Ciprofloxacin 0 0 0 0 0 1 9 9 2 5 2 2 0 0 30
Levofloxacin 0 0 0 0 0 1 13 5 3 4 4 0 0 0 30
Moxifloxacin 0 0 1 6 8 4 5 4 2 0 0 0 0 0 30
parC &g yrA
Ciprofloxacin 0 0 0 0 0 0 3 3 4 29 73 126 55 5 298
Levofloxacin 0 0 0 0 0 1 6 0 13 78 151 37 11 1 298
Moxifloxacin 0 0 0 4 6 3 26 136 87 18 1 1 0 0 282
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ciation with specific common serotypes. We found that
400 out of 622 (64.3%) isolates with Lys-137 parC muta-
tion belonged to serotypes 1, 12, 31, 7A, 9V, 9N and 9L,
whereas only 49 out of 3064 (1.6%) of isolates with no
mutations belonged to these serotypes. Among these
serotypes, 9V, 9N and 9L contained the majority of iso-
lates with Lys-137 parC mutation (285 out of 400).
In Canada, there has been a sustained yearly increase
in the use of the fluoroquinolones for the treatment of
respiratory tract infections in adults during the last dec-
ade [6]. This has been accounted for in large part by the
increased use of levofloxacin and moxifloxacin [6].
Despite the increased use of fluoroquinolones such as
moxifloxacin that preferentially target GyrA, the number
of mutations in the QRDR of the gyrA have gene
remained low [40]. We found only 30 out of 3297
(0.9%) isolates containing mutations in gyrA only that
resulted in an amino acid change in GyrA, with the
most common substitution observed at position 81 (Ser-
81) (70%; 21 out of 30) (Data not shown). The most
common substitutions observed were Ser81Phe or Tyr
in gyrA. The presence of a mutation in gyrA that
resulted in an amino acid change at position 81 was
associated with an approximately two fold increase in
MIC to ciprofloxacin with 52.4% (11 out of 21) of iso-
lates with this mutation resistant to ciprofloxacin. These
data suggest that Ser-81 mutation in gyrA significantly
reduces susceptibility to all fluoroquinolones.
Among isolates with mutations in both parC and
gyrA, majority of these isolates carried amino acid
alterations at Ser-79 and Ser-81 of parC and gyrA,
respectively (214 of 298; 71.8%), followed by amino acid
alterations at Ser-79 and Glu-85 (45 of 298; 15.1%). As
s h o w ni nf i g u r e2 ,i s o l a t e s with mutations Ser-79 in
parC and Ser-81 in gyrA were significantly associated
with higher ciprofloxacin MIC with 69% (145 out of
210) isolates had MIC ≥ 32 mg/L. Similarly, isolates
containing mutations Ser-79 in parC and Glu-85 in
gyrA,o rA s p - 8 3i nparC and Ser-81 in gyrA were also
significantly associated with increased MIC to ciproflox-
acin. Interestingly, we had found 4 isolates containing
mutations Lys-137 in parC and Ser-81 in gyrA,a l lo f
which were resistant to ciprofloxacin. However, MIC
values were similar to the strains with mutations in gyrA
ser-81 only, supporting the fact that mutation in parC
Lys-137 is not associated with a reduction in fluoroqui-
nolone activity.
Table 2 In vitro activity of ciprofloxacin against S. pneumoniae with mutations in the parC gene only.
Ciprofloxacin Minimum Inhibitory Concentration (mg/L)
Number of Isolates
Substitution 0.12 0.25 0.5 1 2 4 8 16 32 64 Total
None 1 6 919 1,863 523 37 2 2 0 1 3,354
Asp-78 0 0 0 0 4 2 0 0 0 0 6
Asp-83 0 0 0 2 19 30 5 0 0 0 56
Lys-137 0 1 176 391 137 16 1 0 0 0 722
Arg-95 0 1 2 2 0 1 0 0 0 0 6
Ser-52 0 0 1 3 4 1 0 0 0 0 9
Ser-79 0 0 0 1 82 84 33 5 2 2 209
Other* 0 0 3 6 7 1 0 0 0 0 17
Tyr-129 0 0 0 3 3 1 0 0 0 0 7
*Mutations at other sites include: Ala-63 (1), Val-66 (2), Met-85 (1), Asn-91 (2) Glu-99 (1), Glu-100 (1), Gly-106 (1), Ser-107 (1), Met-108 (1), Ala-115 (2), Tyr-118 (1),
Arg-122 (1), Leu-130 (1), Glu-135 (1), Thr-138 (1), Ala-158 (1). Of these, two (one with Asn-91-Asp mutation, and one with Ala-115-Pro mutation) had ciprofloxacin
MICs of 4 mg/L, and one (Thr-138-Ile) had a levofloxacin MIC of 2 mg/L. All others had MIC to ciprofloxacin of < 4 mg/L, to levofloxacin of < 2 mg/L, and to
moxifloxacin of < 0.5 mg/L)
Figure 1 Distribution of ciprofloxacin MICs in S. pneumoniae
isolates with a parC only amino acid substitutions. The figure
shows that pneumococcal isolates with substitution at either
position 79 or 83 of parC have four-fold increased ciprofloxacin MIC
compared to isolates with no mutations in parC. On the other hand,
substitution at position 137 of parC does not appear to increase
ciprofloxacin MIC.
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From this study of a large contemporary collection of
pneumococci, we have found that, despite the wide-
spread use of the fluoroquinolones for the treatment of
respiratory tract infections in adults that resistance
remains less the two percent. Also, despite the increase
use of the C-8 methoxy fluoroquinolones including
moxifloxacin and gatifloxacin which primarily target the
type II topoisomerase GyrA, isolates with only muta-
tions in the QRDRs of the gyrA only gene remain infre-
quent. Not all mutations, most frequently Lys-137,
found in the QRDRs of the parC gene of S. pneumoniae
is associated with an increased MIC to fluoroquinolones.
The high prevalence of Lys-137 appears to be due to its
frequent occurrence in common serotypes.
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